Fastlane Launches AI Marketing Platform That Researches, Creates and Runs Campaigns End to End SupportWorld Live 2022 Expo Hall to Display Innovative Products and Services in the Technical Support and Service Management Industry
New Keynote Panel Added on the Topic of Enterprise Service Management; Event Takes Place May…
SHI International Recognized as a 2021 Partner of the Year by Juniper Networks
SOMERSET, N.J.–(BUSINESS WIRE)–SHI International, one of North America’s largest IT solutions providers, today announced that…
StorPool Named Finalist in 7 Categories of Storage Awards XIX
SOFIA, Bulgaria–(BUSINESS WIRE)–StorPool Storage today announced that it is a finalist in multiple categories of…
Taconic Biosciences Appoints Nomura Siam as Distributor in India for All Taconic Animal Models
Improves Access to Critical Rodent Models for Researchers in India RENSSELAER, N.Y., May 10, 2022…
Syneos Health Leaders Recognized by HBA
Healthcare Businesswomen’s Association Spotlights Kasey Boynton and Feni Komline for Biopharma Industry Impact MORRISVILLE, N.C.,…
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,”…
Coherus BioSciences Management to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced…
Outlook Therapeutics to Participate in Retina World Congress 2022
ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial…
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder
Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from MDD or…
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a…
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian…
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC)…
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ:…
The Greenrose Holding Company to Present at Upcoming May Investor Conferences
AMITYVILLE, N.Y., May 10, 2022 (GLOBE NEWSWIRE) — The Greenrose Holding Company Inc. (OTC: GNRS,…
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization…
Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors
Pre-clinical trials based on proprietary combination demonstrate significant suppressive effect on alcohol consumption TORONTO, May…
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
Preclinical study results demonstrated the combination of SciSparc’s CannAmide™ with Clearmind’s MEAI has the potential…
Opthea Presentation at The Retina World Congress 2022
MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage…
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
Data from the completed Phase 1b/2 trial to be presented at the American Society of…